The invention provides anti-inflammatory exosomes that, when administered locally or systemically to a subject diagnosed with an inflammatory disease or disorder, will downregulate the inflammatory process in the subject.
Blood vessels (11, 13) that protrude from an extracted organ or tissue and cannulae (21, 23) for circulation of a perfusion fluid are fastened together by constricting locations that are separated from cut ends of the blood vessels (11, 13) toward a proximal side, viewed from the organ, and perfusion is performed. Consequently, the fastening locations where the cannulae (21, 23) are anchored are separated from the cut ends of the blood vessels (11, 13) that will be anastomosed with blood vessels of a living body, the anastomosis with the blood vessels of the living body can be performed while moving the cannulae (21, 23) into various positions with regard to the blood vessels (11, 13) that protrude from the organ or tissue, and it is possible to perform the task of anastomosis while a perfusion condition is maintained. In this way, anastomosis with blood vessels of a living body can be performed while maintaining a perfused condition for an organ or tissue that has at least one system each of veins and arteries.
The present invention relates to a method for direct transdifferentiation into neurons using metal nanoparticles magnetized from an electromagnetic field, and to a cell therapeutic agent for the treatment of cerebral nerve diseases, comprising neurons differentiated by the method. In the present invention, it was specifically verified that the direct transdifferentiation efficiency into neurons can be remarkably improved through the above method and the symptoms of cerebral nerve diseases, such as a stroke, can be effectively alleviated. Therefore, in the treatment of degenerative cerebral nerve diseases, the target therapy is expected to be implemented through a more fundamental approach.
Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.
Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
The present invention is provided with a transport unit (60) that transports a first sealed container (70) that accommodates cells in a sealed state and automatic culture devices (20, 30) that receive a first sealed container (70) in which cells transported by the transport unit (60) have been accommodated, extract the cells from the first sealed container (70), and culture the cells that have been extracted. The automatic culture devices (20, 30) automatically replace medium.
The present disclosure provides methods for generating embryonic stem cell lines with the integration of a site-specific recombinase deriving from recombinase mouse models. Utilizing methods of the present disclosure, targeting vectors including selection cassettes flanked by respective recognition sites may be removed in ES cells and thus resulting progeny o chimeras would have absence of the selection cassette.
Here is provided a novel differentiation protocol, which was experimentally shown to give rise to corneal epithelial precursor cells or early pigmented RPE precursor cells in defined and xeno-free conditions. The early precursor cells may be further maturated towards corneal epithelium cells, stratified corneal epithelium or mature RPE cells. Such cells may contribute to treatment and research of corneal and retinal conditions, diseases, pathologies as well as toxicology and drug development.
Disclosed are compositions and methods for producing therapeutic fusion proteins in vivo. The compositions and methods disclosed herein are capable of ameliorating diseases by providing therapeutic protein delivery.
A method of cartilage repair, comprising the addition to a surface of cartilage damage of a crosslinkable scaffold material, the scaffold material comprising at least one cytocompatible polymer and at least one of minced tissue and cells, the crosslinking being provided by spontaneous reaction of complementary reactive groups of two types, at least one of these types being present on at least one of the cytocompatible polymer, minced tissue, cells and cartilage surface. The method offers a quick, easy and effective method of cartilage repair.